Newly Public RYAH Medtech Sets Table for Expansion
Robin Lefferts
May 13th, 2021
App, Exclusive, News, Top Story
RYAH Group, Inc. (CSE: RYAH) and its wholly owned subsidiary RYAH Medtech Inc. began trading publicly May 10, 2021 on the Canadian Securities Exchange. The reverse takeover was nearly two years in the making, bringing RYAH’s suite of smart cannabis and plant-based medicine devices (and the accompanying treasure trove of data) to the public markets for the first time.
If there is one thing everyone involved with medical cannabis needs, it’s more data. Solid, factual information from the real world of cannabis treatment will go a long way toward standardizing and documenting what is currently a largely squishy and anecdotal environment. Doctors in location A don’t really know what doctors in location B are discovering. Medical professionals rely on very occasional reports from patients on their experiences using cannabis treatments, and reliable information almost never makes it back to scientists and companies responsible for formulating products.
RYAH is looking to change all of that by creating a feedback loop that provides information to all stakeholders in the world of plant-based medicines. It starts with connected dose-measuring delivery devices like inhalers and vape pens, continues through the RYAH Cloud engine where data is analyzed and parsed, finally informing research, development, and treatment decisions. Let’s take a closer look at the RYAH Medtech business model and see what it has to offer.
Click here to receive an investor presentation and corporate updates
Data Feeds the Science of Plant-Based Medicines
Without rigorous scientific examination and experimentation, plant-based medicines in general and cannabis-based medicines in particular have been somewhat relegated to the back rooms patrolled by herbal shamans offering elixirs based on anecdotal evidence of reported success. The industry needs to replace ‘My cousin swears by it!’ with ‘Research indicates…’ To be sure, that research is happening at an ever-increasing pace, with regulations loosening around the globe and capital flowing into the industry.
Still, there are millions of people who rely on cannabis-derived medicine to treat indications as diverse as PTSD, chronic pain, inflammation, seizures, and sleep disorders. These people are often operating in the dark, trying different strains to find just the right mix without much in the way of medical guidance and adjusting dosages without really knowing why or how. Unbeknownst to these patients, individually or as a group, they actually hold the key to figuring out the complicated puzzle of cannabis medicine. The answer lies in gathering their experiences and unifying them into a dataset that is as large as possible so that trends can be identified, treatments can be evaluated, and conclusions can be made and tested.
RYAH has developed one of the world’s largest databases of medical cannabis session information to provide just such a repository of information. The company has also developed a suite of interconnected delivery devices, including patches, inhalers, and pens, to feed even more data into the system. RYAH’s Cloud engine constantly churns the data, producing digestible and actionable information to researchers, cannabis producers, product designers, medical professionals, and patients themselves. The whole ecosystem is designed to maximize the effectiveness of current treatments while enabling the efficient development of the next generation of plant-based medicinal products.
Click here to receive an investor presentation and corporate updates
Expansion on Tap
RYAH recently announced a definitive wholesale supply and distribution agreement with Medical Kiwi Ltd., a leading medical cannabis company in New Zealand. Beyond selling and distributing RYAH products throughout the country, the agreement allows the two companies to explore medical device registration there for RYAH’s proprietary delivery devices. If that comes to pass, it would be the first such device registered for medical use in New Zealand.
“Our new partnership with Medical Kiwi Ltd in New Zealand further expands our global clinical and distribution network for plant-based medicine and digital patient care,” said Gregory Wagner, CEO of RYAH Group Inc. and of RYAH Medtech, Inc. “In December 2019, the New Zealand Government passed legislation to improve access to medical cannabis products. Our new relationship with Medical Kiwi presents an opportunity for both parties to drive innovation and to deliver cutting edge plant-based medical solutions in New Zealand.“
Deals such as this are the prototype for RYAH’s growth potential to become a reality. Whether it’s distributors in a new market, research organizations such as universities and pharma companies, or medical cannabis collectives and treatment centers, the reliability of RYAH’s delivery devices combined with the access to large datasets should be of interest to a wide range of potential clients.
With the new public listing, RYAH’s expansion may be picking up steam. Focusing on distribution and clinical trials in European and US markets, along with moves into new markets like the New Zealand arrangement, will go a long way toward growing both the size of the dataset and the company’s top line. The access to public capital markets along with the transparency and validation provided by the pubco listing should only help in RYAH’s quest to inform and advance the plant-based medical community.
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Robin Lefferts
Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Helix TCS, Inc. (OTCQB: HLIX) provides software and technology platforms for the cannabis industry.
Future Farm Technologies Inc. develops and acquires technologies that position it as a leader in the evolution of Controlled Environment Agriculture (CEA).
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
